Agreements support lower prices for CSL therapies and reflect CSL's $1.5 billion plan to expand its U.S. manufacturing capacity in Illinois
KING OF PRUSSIA, Pa., - August 31, 2026 – CSL (ASX:CSL; USOTC:CSLLY) today announces agreements with the U.S. government to lower the cost of medicines in the U.S., reflecting CSL’s previously announced plan to expand its plasma therapy production capacity in Kankakee, Illinois.
Under an agreement with the U.S. Department of Health and Human Services, CSL will provide the Medicaid program with access to its current medicines at prices comparable to those available in other developed countries. It also will similarly price any newly launched therapies for all payers in the U.S.
In addition, CSL has entered into an Onshoring Agreement with the U.S. Department of Commerce that reflects CSL’s plans to invest $1.5 billion to expand its manufacturing presence in Kankakee, Illinois. The project will substantially increase CSL's ability to produce immunoglobulins and albumin for people living with rare diseases and serious conditions. The investment will incorporate next-generation technologies designed to improve manufacturing efficiency and support growing patient needs. The project is expected to create at least 300 new pharmaceutical manufacturing jobs and approximately 800 construction and related jobs, reinforcing CSL's long-standing commitment to advancing manufacturing and economic growth in the United States.
“At CSL, our focus has always been the patients who depend on our therapies. These agreements provide a sustainable and stable access framework to important medicines for people living with rare diseases and serious conditions while strengthening the manufacturing capabilities, supply infrastructure and scientific innovation required to deliver those therapies reliably,” said Diego Sacristan, CSL Global Chief Commercial Officer. “They also build on CSL's continued investment in the United States, including our $1.5 billion expansion in Illinois.”
The agreements provide CSL with additional certainty regarding its exposure to U.S. drug pricing and certain Section 232 tariffs. The company does not anticipate any material impact during fiscal year 2027. The increased certainty enables CSL to proceed with its significant planned investments in its U.S. manufacturing capacity, plasma collection infrastructure, and supply chain innovation, all of which will strengthen CSL’s ability to deliver critical medicines to patients in the U.S. today and in the future.
A Strong and Growing U.S. Presence
CSL today employs approximately 19,000 people across 44 U.S. states, representing about 60 per cent of the company's global workforce. Since 2018, CSL has invested more than $3.1 billion in its U.S. operations, creating more than 6,500 American jobs and expanding its manufacturing, research and plasma collection capabilities nationwide.
About CSL
CSL (ASX: CSL; USOTC: CSLLY) is a leading global biotechnology company with a dynamic portfolio of life-saving medicines, including therapies that treat hemophilia and immune deficiencies, vaccines that help prevent influenza, and treatments in iron deficiency, dialysis and nephrology. Through its businesses CSL Behring, CSL Seqirus and CSL Vifor, CSL provides products to patients in more than 100 countries and employs almost 29,000 people worldwide. CSL is driven by its promise to develop and deliver innovations that improve and save lives. CSL's purpose is grounded in patient focus, innovation, integrity, collaboration and superior performance.
Media Contacts
Ken Inchausti, CSL Behring
Mobile: +1 267.524.5750
Email: ken.inchausti@cslbehring.com
Brett Foley, CSL Limited
Mobile: +61 461 464 708
Email: media@csl.com.au